Another company has caught the eye of Max Hodak, the cofounder of Neuralink. Despite claiming there’s no animosity between him and his former company, his recent investments tell a different story.
Hodak recently secured $47 million in funding for a brain interface venture called Science Corp. Additionally, he has personally invested in Synchron, another competitor of Neuralink. In a blog post, Hodak expressed his excitement to support Synchron and help them succeed in any way he can.
Synchron distinguishes itself from Neuralink by accessing the brain through blood vessels instead of implanting a chip via the skull. The company has already initiated human trials and achieved impressive results, such as enabling a man with ALS to tweet using their technology.
On the other hand, Neuralink has yet to reach human trials, with Elon Musk announcing plans to start implanting chips in 2022 without a specific timeline. Hodak’s involvement with Synchron adds to the challenges Neuralink has been facing recently, raising doubts about the company’s future.
As the competition between Neuralink and its rivals intensifies, it remains to be seen which company will lead the way in brain-computer interface technology. Hodak’s strategic investments could potentially shape the future of this innovative industry.
For more insights into the rivalry between Neuralink and its competitors, check out the details in the article from Insider. And if you’re curious about the inner workings of Neuralink, former employees have some interesting stories to share about working under Elon Musk’s leadership.
The race to revolutionize brain-computer interfaces is heating up, and Hodak’s involvement in the game-changing advancements is definitely worth keeping an eye on.
